Inhibikase Therapeutics Inc. announced the election of Anthony Zook, former head of Global Commercial Operations at AstraZeneca and past CEO of North America Operations for AstraZeneca and President of MedImmune, to its board of directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | -7.84% | -16.57% | +11.02% |
06-05 | Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline | CI |
05-21 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.02% | 10.17M | |
+40.80% | 53.67B | |
-8.05% | 38.76B | |
+35.79% | 38.86B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Inhibikase Therapeutics, Inc. Elects Anthony Zook to its Board of Directors